Cargando…
Persistent progress
The highly effective and safe mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines draw on decades of painstaking research to overcome the many hurdles for delivering, expressing, and avoiding toxicity of therapeutic mRNA. Cell editor Nicole Neuman talked with Dr. Katalin...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Elsevier Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462135/ https://www.ncbi.nlm.nih.gov/pubmed/34562365 http://dx.doi.org/10.1016/j.cell.2021.08.006 |
| _version_ | 1784572135521386496 |
|---|---|
| collection | PubMed |
| description | The highly effective and safe mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines draw on decades of painstaking research to overcome the many hurdles for delivering, expressing, and avoiding toxicity of therapeutic mRNA. Cell editor Nicole Neuman talked with Dr. Katalin Karikó and Dr. Drew Weissman, recipients of the 2021 Lasker∼DeBakey Clinical Medical Research Award, to learn more about their quest to develop mRNA-based therapeutics, which led them to the crucial discovery that modification of mRNA could prevent toxicity and increase expression. This conversation has been adapted for print below, with editing for clarity, accuracy, and length. |
| format | Online Article Text |
| id | pubmed-8462135 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84621352021-09-27 Persistent progress Cell Conversations The highly effective and safe mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines draw on decades of painstaking research to overcome the many hurdles for delivering, expressing, and avoiding toxicity of therapeutic mRNA. Cell editor Nicole Neuman talked with Dr. Katalin Karikó and Dr. Drew Weissman, recipients of the 2021 Lasker∼DeBakey Clinical Medical Research Award, to learn more about their quest to develop mRNA-based therapeutics, which led them to the crucial discovery that modification of mRNA could prevent toxicity and increase expression. This conversation has been adapted for print below, with editing for clarity, accuracy, and length. Elsevier Inc. 2021-10-14 2021-09-24 /pmc/articles/PMC8462135/ /pubmed/34562365 http://dx.doi.org/10.1016/j.cell.2021.08.006 Text en © 2021 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Conversations Persistent progress |
| title | Persistent progress |
| title_full | Persistent progress |
| title_fullStr | Persistent progress |
| title_full_unstemmed | Persistent progress |
| title_short | Persistent progress |
| title_sort | persistent progress |
| topic | Conversations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462135/ https://www.ncbi.nlm.nih.gov/pubmed/34562365 http://dx.doi.org/10.1016/j.cell.2021.08.006 |